Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial.

Udell JA, Morrow DA, Braunwald E, Swedberg K, Bode C, Rifai N, Brunel PC, Prescott MF, Ren F, Hoffman EB, Scirica BM.

Clin Chem. 2013 Jun;59(6):959-67. doi: 10.1373/clinchem.2012.199729. Epub 2013 Mar 18.

2.

Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.

Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJ, Lopez-Sendon J, Swedberg K, Ogorek M, Rifai N, Lukashevich V, Maboudian M, Cannon CP, McCabe CH, Braunwald E.

Eur Heart J. 2010 Aug;31(16):1993-2005. doi: 10.1093/eurheartj/ehq190. Epub 2010 Jun 17.

PMID:
20558431
3.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 . Epub 2008 Feb 27.

PMID:
18307835
4.

Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.

Crespo MJ, Cangiano JL, Altieri PI, Escobales N.

J Cardiovasc Pharmacol. 2012 Jun;59(6):547-52. doi: 10.1097/FJC.0b013e31824e5273.

PMID:
22370958
6.

Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.

Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB.

J Am Soc Hypertens. 2012 Sep-Oct;6(5):338-45. doi: 10.1016/j.jash.2012.07.003.

PMID:
22995802
7.

Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction.

Connelly KA, Advani A, Advani S, Zhang Y, Thai K, Thomas S, Krum H, Kelly DJ, Gilbert RE.

Cardiovasc Ther. 2013 Apr;31(2):84-91. doi: 10.1111/j.1755-5922.2011.00292.x. Epub 2011 Jul 4.

PMID:
21884026
8.

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J; ATMOSPHERE Investigators.

Eur J Heart Fail. 2011 Jan;13(1):107-14. doi: 10.1093/eurjhf/hfq212.

9.

Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.

Azizi M, Ménard J, Bissery A, Guyene TT, Bura-Rivière A.

Clin J Am Soc Nephrol. 2007 Sep;2(5):947-55. Epub 2007 Aug 8.

10.

Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.

Higashikuni Y, Takaoka M, Iwata H, Tanaka K, Hirata Y, Nagai R, Sata M.

Hypertens Res. 2012 Jan;35(1):62-9. doi: 10.1038/hr.2011.136. Epub 2011 Aug 11.

PMID:
21833001
11.

Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats.

Koçak G, Azak A, Astarcı HM, Huddam B, Karaca G, Ceri M, Can M, Sert M, Duranay M.

Ther Apher Dial. 2012 Feb;16(1):75-80. doi: 10.1111/j.1744-9987.2011.01031.x.

PMID:
22248199
12.

Aliskiren and valsartan combination therapy for the management of hypertension.

Epstein BJ.

Vasc Health Risk Manag. 2010 Sep 7;6:711-22. Review.

13.

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.

Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A.

Am J Hypertens. 2007 Jan;20(1):11-20.

PMID:
17198906
14.
15.

Dual inhibition of the renin system by aliskiren and valsartan.

Birkenhäger WH, Staessen JA.

Lancet. 2007 Jul 21;370(9583):195-6. No abstract available.

PMID:
17658374
16.

Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.

Giles TD, Alessi T, Purkayastha D, Zappe D.

J Clin Hypertens (Greenwich). 2012 May;14(5):299-306. doi: 10.1111/j.1751-7176.2012.00608.x. Epub 2012 Mar 16.

17.

[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].

Dralova OV, Maksimov ML, Derbentseva EA, Ermolaeva AS, Starodubtsev AK.

Eksp Klin Farmakol. 2011;74(4):14-7. Russian.

PMID:
21678653
18.

Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.

Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.

Rom J Intern Med. 2005;43(3-4):187-98.

PMID:
16812979
19.

Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction).

Schroten NF, Damman K, Hemmelder MH, Voors AA, Navis G, Gaillard CA, van Veldhuisen DJ, Van Gilst WH, Hillege HL.

Am Heart J. 2015 May;169(5):693-701.e3. doi: 10.1016/j.ahj.2014.12.016. Epub 2015 Jan 7.

PMID:
25965717
20.

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A.

Expert Opin Pharmacother. 2007 Apr;8(5):529-35. Review.

PMID:
17376010

Supplemental Content

Support Center